Exenatide vs Retatrutide

Molecule comparison

Last updated 2026-05-28 15:46 UTC

Exenatide is a GLP-1 receptor agonist already approved by the FDA to treat type 2 diabetes, available as Byetta or Bydureon. Retatrutide is an experimental drug in development that targets three receptors (GIP, GLP-1, and glucagon) but has not yet been approved for any use.

AI summary of the sources below.

	Exenatide	Retatrutide
Mechanism	GLP-1 receptor agonist	GIP, GLP-1 and glucagon receptor triple agonist
Status	Approved	Pipeline
Branded products	byetta, bydureon	—

Compare full details on the Exenatide and Retatrutide pages.